Argenx Se (ARGX) Total Non-Current Liabilities (2016 - 2026)

Argenx Se (ARGX) posted quarterly Total Non-Current Liabilities of $40.0 million for Q2 2026, down 99.89% year-on-year from $37.9 billion in Q2 2025, and up 2.56% on a QoQ basis from $39.0 million in Q4 2025.

Argenx Se (ARGX) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends

Argenx Se (ARGX) has reported Total Non-Current Liabilities for 11 consecutive years, with $40.0 million the latest figure, recorded in Q2 2026.

  • Quarterly Total Non-Current Liabilities fell 99.89% year-over-year to $40.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $40.0 million (down 99.89% YoY) and the FY2025 annual result came in at $39.0 million, up 13.63% from the prior year.
  • Total Non-Current Liabilities grew to $40.0 million in Q2 2026 per ARGX's latest filing, from $39.0 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for ARGX reached as high as $37.9 billion in Q2 2025 and fell as low as $14.4 million in Q2 2022.
  • A 5-year average of $4.2 billion and a median of $34.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2025 — Total Non-Current Liabilities jumped 109282.39% — and 2026, when it plunged 99.89%.
  • Year by year, Total Non-Current Liabilities stood at $18.3 million in 2022, then grew by 20.09% to $22.0 million in 2023, then soared by 56.31% to $34.3 million in 2024, then rose by 13.63% to $39.0 million in 2025, then rose by 2.56% to $40.0 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $40.0 million, $39.0 million, and $37.9 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn 4.05 Bn

Historic Data

Download Data
DateValue
Jun 30, 2026 40.00 Mn
Dec 31, 2025 39.00 Mn
Jun 30, 2025 37.94 Bn
Dec 31, 2024 34.32 Mn
Jun 30, 2024 34.68 Mn
Dec 31, 2023 21.96 Mn
Jun 30, 2023 17.95 Mn
Dec 31, 2022 18.29 Mn
Jun 30, 2022 14.42 Mn
Dec 31, 2021 14.81 Mn
Jun 30, 2021 17.05 Mn
Dec 31, 2020 255.37 Mn
Jun 30, 2020 235.89 Mn
Dec 31, 2019 253.35 Mn
Jun 30, 2019 274.66 Mn
Dec 31, 2018 7,965.68
Jun 30, 2018 36,080.24
Dec 31, 2017 2.11 Mn
Jun 30, 2017 1,443.21
Dec 31, 2016 14.53 Mn